Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158520 | 1.00 | TACR1 (0.45) | TACR1GPR119HDAC1HDAC2CYP3A4 | |
| SCHEMBL1969990 | 0.88 | TACR1 (0.47) | TACR1GPR119HDAC1HDAC2CYP3A4 | |
| SCHEMBL5159214 | 0.88 | TACR1 (0.47) | TACR1GPR119HDAC1HDAC2CYP3A4 | |
| SCHEMBL5226257 | 0.88 | TACR1 (0.47) | TACR1GPR119HDAC1HDAC2CYP3A4 | |
| SCHEMBL4408595 | 0.87 | TACR1 (0.48) | TACR1GPR119HDAC1HDAC2CYP3A4 | |
| SCHEMBL4153158 | 0.87 | TACR1 (0.48) | TACR1GPR119HDAC1HDAC2CYP3A4 | |
| SCHEMBL4407576 | 0.87 | TACR1 (0.48) | TACR1GPR119HDAC1HDAC2CYP3A4 | |
| SCHEMBL1971268 | 0.87 | TACR1 (0.48) | TACR1GPR119HDAC1HDAC2CYP3A4 | |
| SCHEMBL5005980 | 0.87 | TACR1 (0.48) | TACR1GPR119HDAC1HDAC2CYP3A4 | |
| SCHEMBL4408589 | 0.87 | TACR1 (0.48) | TACR1GPR119HDAC1HDAC2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | TACR1 2/4885GPR119 522/4885HDAC1 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.